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Purpose of the study
MOTIVATE 1 and 2 are randomized, double-blind, pla-
cebo (PBO)-controlled Phase III studies assessing the effi-
cacy and safety of maraviroc (MVC) in TE patients with R5
HIV-1. In both studies, MVC (QD/BID) + optimized back-
ground therapy (OBT) demonstrated significantly greater
virological and immunological efficacy and a similar
safety profile compared with PBO+OBT at weeks 24 and
48 [1].
Methods
1,076 patients with triple drug-class experience and/or tri-
ple-class resistance, R5 virus (Trofile™), and HIV-1 RNA
≥5,000 copies/mL were randomized 1:2:2 to PBO, MVC
QD or BID. All patients received OBT (3–6 antiretrovirals
+/- low-dose ritonavir; darunavir/r not permitted due lack
of PK data). The study was unblinded after week 48 (pri-
mary end-point). Patients in both MVC arms who had not
experienced treatment failure through week 48 were
rolled over to open-label MVC BID, but are referred to
below by their baseline (BL) randomization assignment.
The PBO arm contains patients who were virologically
suppressed at week 48 and remained on OBT through
week 96. After week 48, substitutions in OBT were
allowed in all arms.
Summary of results
More patients in the MVC arms maintained HIV-1 sup-
pression (to <400 and <50 copies/mL) through week 96
than those in the PBO arm. Fewer patients in the MVC
arms experienced virologic failure between week 48 and
96 compared with the PBO arm. Incidence of SAEs, Cate-
gory C events and malignancies were similar among treat-
ment arms even when unadjusted for exposure, which was
significantly greater in each of the MVC arms compared
with the PBO arm. See table in Figure 1.
Conclusion
MVC+OBT resulted in durable viral suppression through
week 96 in these TE patients with R5 HIV-1. Pooled anal-
yses revealed no new or unique safety signals between 48
and 96 weeks. Serious adverse events, Category C events
and malignancies occurred with similar frequency among
treatment groups.
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